CD7 expression tied to poorer outcomes with newly diagnosed leukemia

CD7 expression is connected to poorer outcomes in patients with newly diagnosed acute myeloid leukemia (AML), in accordance with a take into story published on-line April 11 within the British Journal of Haematology.

Wei-Ying Jen, B.M., B.Ch., from the University of Texas MD Anderson Cancer Center in Houston, and colleagues aloof lumber along with the circulation cytometry files on 901 patients with AML and examined aberrant CD7 expression on leukemic blasts.

The researchers chanced on that 29.2% had blasts decided for CD7. Detrimental threat turn out to be as soon as extra likely (64.6 versus 55.6%) and favorable threat turn out to be as soon as much less likely (15.2 versus 24.1%) with CD7-decided AML by European LeukemiaNet 2022 criteria.

Additionally, total survival turn out to be as soon as unsightly (11.9 versus 19.0 months). Moderate instability over time turn out to be as soon as seen, with 30.4% losing and 19.0% gaining CD7 at relapse.

“In abstract, we file on a neat population of AML with consideration to CD7 expression, genomic profiles and patient outcomes,” the authors write.

“The retrospective nature of the take into story and the preference of associated cytomolecular characteristics require a neat sample size, and the identification of any associations would require further evaluation and affirmation in self reliant datasets.”

© 2024 HealthDay. All rights reserved.